Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002155 · ClinicalTrials.gov registry record · NA

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

A NA study of HIV Infections, sponsored by Merck Sharp & Dohme.

Completed
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT00002155 is a NA study of HIV Infections that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 600 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002155, a NA study of HIV Infections, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Lamivudine
  • DRUG Indinavir sulfate

Study Locations (1)

New Jersey

  • Merck & Co Inc - Whitehouse Station

Trial Details

FieldValue
Enrollment Target 600 participants
Phase NA

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002155

The ClinicalTrials.gov registry entry for NCT00002155 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.

NCT00002155 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002155 about?

NCT00002155 is a clinical study titled "A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC". To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.

What is the current status of trial NCT00002155?

This trial is currently completed. It is a NA study. The enrollment target is 600 participants.

What conditions does trial NCT00002155 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002155?

The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG).

Who is sponsoring clinical trial NCT00002155?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002155 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.